Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Gastrointestinal 1

Conditions

Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroblastoma 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 10Irinotecan 8Melphalan 7Vincristine 6Temozolomide 6Doxorubicin 6Busulfan 6Topotecan 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Ifosfamide 4Filgrastim 4Etoposide 4Albumin-Bound Paclitaxel 4Trabectedin 3Sirolimus 3Nivolumab 3130-nm albumin-bound paclitaxel 3pegfilgrastim 2olaparib 2fludarabine phosphate 2fludarabine 2eribulin 2cixutumumab 2abemaciclib 2X-Rays 2Radiotherapy, Intensity-Modulated 2Peripheral Blood Stem Cell Transplantation 2Magnetic Resonance Spectroscopy 2Granulocyte-Macrophage Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sarcoma, Ewing × Cytokines × Clear all
NCT02890758 2023-02-21

Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803

Case Comprehensive Cancer Center

Phase 1 Completed
14 enrolled
GastrointestinalLymphoidMyeloidOther hematologic neoplasmPlasma cellSarcoma

Colonic Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Rectal Neoplasms, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡